


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

| | |
|-------------------|--|
| USAN | DABIGATRAN |
| PRONUNCIATION | da bye gat' ran |
| THERAPEUTIC CLAIM | Deep vein thrombosis after surgery, venous thromboembolic events, stroke prevention in atrial fibrillation |

CHEMICAL NAMES

1. β -Alanine, *N*-[[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1*H*-benzimidazol-5-yl]carbonyl]-*N*-2-pyridinyl-
2. 3-[[2-[[[4-(4-carbamimidoylphenyl)amino]methyl]-1-methyl-1*H*-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propanoic acid

STRUCTURAL FORMULA



| | |
|----------------------------|---|
| MOLECULAR FORMULA | C ₂₅ H ₂₅ N ₇ O ₃ |
| MOLECULAR WEIGHT | 471.5 |
| TRADEMARK | Pradaxa® |
| MANUFACTURER | Boehringer Ingelheim Pharma GmbH & Co. KG and Bidachem S.p.A. |
| CODE DESIGNATION | BIBR 953 ZW |
| <u>CAS</u> REGISTRY NUMBER | 211914-51-1 |
| WHO NUMBER | 8028 |
| GBK | |